Filters
Recent therapy options in ALK-positive non-small cell lung cancer
. ALK inhibitors became a standard therapy in first line treatment, second generation ALK inhibitors are available in clinical practice and higher lines are tested. This article would be a summari...
Respiratory systems
- 2018 •
- Jost •
- Link
Rok uplatnění
Jost - Ostatní články v recenzovaných periodicích
Výsledek na webu
When not even four ALK inhibitors are enough
ALK inhibitors (ceritinib, alectinib, lorlatinib) did not prevent progressionOur case report describes a non-smoker with generalized pulmonary adenocarcinoma with ALK translocation. After the first two lines of ch...
Respiratory systems
- 2020 •
- JSC •
- Link
Rok uplatnění
JSC - Článek v periodiku v databázi SCOPUS
Výsledek na webu
Advanced lung cancer as chronic disease
Our report presents a case of a patient treated with ALK inhibitor crizotinib in the second line according to the EML4-ALK proven translocation. Tumor stopped a response to this therapy after a few months, probably...
FC - Pneumologie
- 2015 •
- Jx
Rok uplatnění
Jx - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
Case report of a patient with metastatic non-small cell lung cancer with positive ALK gene rearrangement treated in the first line with alectini
ALK gene rearrangement (anaplastic lymphoma kinase) is a genetic change in non-small cell lung cancer (NSCLC) that predicts the effectiveness of targeted ALK inhibitor therapy. Nowadays, we have three generations o...
Oncology
- 2020 •
- JSC •
- Link
Rok uplatnění
JSC - Článek v periodiku v databázi SCOPUS
Výsledek na webu
Ceritinib - a new hope for patients with ALK-positive translocation of non-small-cell lung cancers
containing EML-4 ALK gene translocation. This type of tumour is commonly demonstrated in 3-5% of patients with lung adenocarcinoma. Ceritinib is an effective second-generation ALK tyrosine kinase inhibitor.It is a...
FC - Pneumologie
- 2015 •
- Jx
Rok uplatnění
Jx - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
Patient-derived xenograft models of ALK plus ALCL reveal preclinical promise for therapy with brigatinib
survival of 49% and a median survival of 23.5 months. The second-generation ALK inhibitor brigatinib shows superior penetration of the blood-brain barrier unlike the first-generation drug crizotinib and h...
Hematology
- 2023 •
- Jimp •
- Link
Rok uplatnění
Jimp - Článek v periodiku v databázi Web of Science
Výsledek na webu
Case reports of patients with ALK-positive NSCLC and brain metastases
with the intracranial efficacy of individual ALK inhibitors.The present case reports describe a young male and a young female patient diagnosed with generalized non-small cell lung adenocarcinoma with brain metastases and...
Oncology
- 2023 •
- JSC •
- Link
Rok uplatnění
JSC - Článek v periodiku v databázi SCOPUS
Výsledek na webu
Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target
to apoptosis; co-treatment in vitro with the ALK inhibitor crizotinib led to additive therapy for future use in the circumvention of ALK inhibitor resistance. Indeed as a second-line druggable target in <...
Hematology
- 2021 •
- Jimp •
- Link
Rok uplatnění
Jimp - Článek v periodiku v databázi Web of Science
Výsledek na webu
Crizotinib - Still "gold standard" for patients with pulmonary adenocarcinoma with ALK translocation?
Crizotinib is a tyrosine kinase inhibitor targeting ALK translocation. Based with ALK translocation in the first as well as the second line of treatment. Its toxic to the form of payment, it has been used exclusive...
Respiratory systems
- 2017 •
- Jost
Rok uplatnění
Jost - Ostatní články v recenzovaných periodicích
Two years longer and peaceful life thanks to alectinib
by a high mortality rate. In patients with non-small cell lung cancer with confirmed ALK translocation, a significant effect of targeted therapy with tyrosine kinase inhibitors (TKI) has been shown. Alektinib, a second-
Respiratory systems
- 2022 •
- Jost •
- Link
Rok uplatnění
Jost - Ostatní články v recenzovaných periodicích
Výsledek na webu
- 1 - 10 out of 176 742